Brace yourself: Drug prices are set to soar again, despite promises of relief.
While the Trump administration touts its Most Favored Nation (MFN) policy as a groundbreaking victory for affordable healthcare, a new report from 3 Axis Advisors, first reported by Reuters, paints a different picture. The analysis reveals that drugmakers are planning to raise prices on at least 350 medications in 2026, a significant increase from the 250 drugs slated for markups last year. This comes despite many pharmaceutical companies pledging to offer more favorable prices under the MFN policy, which aims to cap prices at the lowest global rate.
But here's where it gets controversial: Several of the companies planning these price hikes, including Pfizer and GSK, are among those who agreed to the MFN policy. This raises questions about the true impact of the policy and whether it's doing enough to address the root causes of skyrocketing drug costs.
The median price increase is expected to be around 4%, but this doesn't account for rebates to pharmacy benefit managers and other discounts, potentially masking the true burden on consumers. While the MFN policy applies to the Medicaid program, its impact on Medicaid patients may be minimal, as the program already guarantees the lowest price offered to any commercial payer.
And this is the part most people miss: Critics argue that the MFN policy merely scratches the surface of the problem. The Centre for Economic Policy Research points out that patent monopolies are the primary driver of exorbitant drug costs, an issue neither the MFN policy nor drug price negotiation directly addresses.
President Trump hailed the MFN agreements as "the greatest victory for patient affordability in the history of American health care," praising pharmaceutical companies for their cooperation. However, the looming price hikes suggest that the battle for truly affordable medications is far from over.
The launch of the TrumpRx direct-to-consumer platform in 2026 may offer some relief, but its effectiveness remains to be seen.
What do you think? Is the MFN policy a step in the right direction, or is it a band-aid solution to a much deeper problem? Let us know in the comments.
